Clinical Trial Update: Effect of Anti CD20 in Pemphigus Desease [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update reporting results for anti-CD20 therapy in pemphigus across phase 2 and phase 3, with the study now completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pemphigus

Drugs mentioned

• Rituxan (rituximab)

Snippet

Sponsor: University Hospital, Rouen | Conditions: Pemphigus | Phase 2, Phase 3 | Status: COMPLETED